Reuters Does Report on Cerebain Biotech Corp. https://twitter.com/SamKnows7/status/1237803256845414402
Cerebain has a patent-pending device that is implanted in the omentum, a protective layer of skin that protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease.
Cerebain will evaluate the effect of omental stimulation at different intervals and levels of stimulation to determine the device’s ability to slow, stop or reverse the progression of Alzheimer’s Disease on patients.
About the Omentum
Generally described as a protective layer in the abdomen, the omentum covers the intestines, hangs on to the stomach and can be lifted like a flap. While the omentum is not a well-recognized body part, it can play important healing and protective roles for its host.
Protection: The omentum has abundant blood and lymphatic vessels, and can move flexibly throughout the abdomen to protect organs from threat and injury.
Healing: Additionally, it contains the largest supply of stem cells in the adult body. Because of its abundant blood supply, surgeons have long used the omentum to patch internal injuries sustained to other parts of the body.
Publications on the Omentum and it's Regenerative Powers
"Omentum a powerful biological source in regenerative surgery"
International Patent License
"" International Application Number PCT/US2009/031462 (published as WO 2009/0094340), titled “Omentum and Use Thereof”;""
Patent is a 20 Year Internatinal Agreement; ""Subject to the payment of fees under this title, such grant shall be for a term beginning on the date on which the patent issues and ending 20 years from the date on which the application for the patent was filed in the United States or""
Patent-pending technology has allowed for the development of a medical device that can
be implanted using a minimally invasive procedure.
Once implanted via what will probably be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.
Cerebain has a manufacturing agreement with Sonos Medical, a trusted and reliable medical device supplier.
The Company is now in the process of preparing for initial clinical trials that will most likely occur at multiple medical centers in Europe.
Potential for a Personalized Approach to
Treatment for Alzheimer’s Disease Patients
As clinical trials are conducted and variables are put into play (e.g., frequency of stimulation, duration, location, etc.,) we may find that individuals respond differently and require individualized treatment plans. Cerebain’s device can potentially provide this, making our ability to positively impact the lives of as many Alzheimer’s Disease patients as possible.
In 2010 Cerebain Biotech licensed patent-pending technology for an implantable device that stimulates the omentum, and can be adjusted non-invasively to account for a range of factors, including frequency, strength of stimulation and location.
Existing therapeutics have been unable to halt disease progression or extend life in a meaningful way
Cerebain’s novel device approach is supported by research and patient outcomes
Clinical evidence supports the Company’s working approach, that omentum stimulation improves cognitive function in patients with dementia, including Alzheimer’s Disease
Minimally invasive, one-time device implantation will overcome challenges associated with previous omentum stimulation procedures that are highly invasive
Patent-pending technology with broad applicability
Recent scientific breakthroughs regarding the potential identification of gene-specific protein increases prior to on-set of symptoms, could compliment our work
Early diagnosis is key to helping patients maintain quality of life http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-genetics-fact-sheet
Experienced management and advisory teams with the expertise to move the clinical program forward efficiently and effectively
Disclosures and Filings
Eric Clemons, President and CEO
Mr. Clemons has a long history building and growing companies across multiple industries. Prior to assuming leadership of Cerebain, he served as President and Chief Operating Officer for GTC Telecom Corp, a publicly traded Nevada Corporation that operated out of Costa Mesa, CA. During his tenure, Mr. Clemons was instrumental in growing the company’s annual revenues from $500,000 per year to over $17 million per year.
It was Cerebain technology, which offers a completely new way of approaching the development of an effective Alzheimer’s disease treatment that captured Mr. Clemons’ imagination, triggering his move into the life sciences arena.
“While there have been some very recent key learnings in the Alzheimer’s treatment space, the fact is that the disease remains the only top ten killer in the United States with no effective treatments currently available and no way to halt or slow progression,” Clemons said. “We are hopeful that our device, which will focus on the impact of omental stimulation and cognitive function in Alzheimer’s Disease patients, can change that.”
Wesley Tate – former - Chief Financial Officer
Prior to joining Cerebain Biotech, Mr. Tate was the owner of Strategic Business Associates, a Tennessee-based consultancy offering business management and growth services to start-up and early-stage companies.
Over the course of his career Mr. Tate has held key managerial positions at both healthcare and telecoms companies. This includes Chief Financial Officer for HST Global, Inc., a development-stage biotechnology company located in Virginia; and Executive Vice President and Chief Operating Officer for InnerLight Inc., a life science company located in Utah.
Mr. Tate received his Bachelor of Science degree from the University of Tennessee, Knoxville, with majors in Finance and Psychology, and earned his Masters of Business Administration from the University of Tennessee, Knoxville, with concentrations in Finance and Management.
He is proud to have served his country as a member of the United States Army.
Mr. Tate resigned from Cerebain in July of 2019, he did however agree to assist in any way possible during the transition period, as best as anyone has been able to determine, he is still functioning at CBBT is some sort or manner.
Cerebain engaged with NMS Consulting -
""NMS Consulting will also advise Cerebain on a corporate restructuring and cost savings plan, under which it will identify opportunities to optimize operations, drive efficiency and reduce costs.""
A/S 1,250,000,000 03/26/2020
O/S 643,830,191 03/26/2020
Restricted 5,529,037 03/26/2020
Unrestricted 638,301,154 03/26/2020
CBBT - Historical Prices / Volume